David Campbell

Phenomix Corp. is a biopharmaceutical company focused on the discovery, development and commercialization of novel small-molecule product candidates directed toward clinically validated targets in significant therapeutic markets. It's internally discovered product candidates are designed to have improved efficacy, safety or convenience relative to existing therapies and other product candidates in clinical development. Its lead product candidate, dutogliptin tartrate, is a dipeptidyl peptidase-4, or DPP-4, inhibitor that it is developing as an oral, once-daily treatment for Type 2 diabetes. Its Phase 2b clinical trial of dutogliptin demonstrated statistically significant reductions in HbA1c when administered in combination with existing drugs for the treatment of Type 2 diabetes. The company commenced its Phase 3 clinical program in the third quarter of 2008. Its second product candidate, PHX1766, is a protease inhibitor currently in Phase 1 of clinical development for the treatment of hepatitis C virus, or HCV, infection. The company intends to maximize the value of its product candidates through independent development, licensing and other partnership opportunities. These may include co-development or co-marketing agreements, licensing agreements with pharmaceutical and biotechnology companies that possess established development and commercialization capabilities or direct commercialization by building its own sales and marketing force.

ActivX Biosciences, Inc. develops pharmaceutical products. It discovers and develops small molecule drugs for major unmet medical needs. The company was founded in 2000 and is located in La Jolla, CA

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Part of GSK Plc, Affymax Research Institute is a company that researches and develops pharmaceutical products. The company is based in Palo Alto, CA. Affymax Research Institute was acquired by Affymax, Inc. from GSK Plc on July 30, 2001.

Afraxis, Inc. operates as a contract research organization (CRO), specializes in preclinical efficacy evaluations (in vivo and in vitro), neurotoxicity evaluations, and structure-efficacy relationship (SER)-driven medicinal chemistry. It develops Afraxis ESP, an enhanced spine analysis platform that quantifies the morphology and maturity of synaptic dendritic spines, which are fundamental to information processing by neural synapses in the brain. The company was founded by Jay B. Lichter, Carmine Stengone, Susumu Tonegawa and Ben Vollrath in 2007 and is headquartered in San Diego, CA.

Thyritope Biosciences, Inc. develops therapeutics for Graves’ Orbitopathy, an auto-immune disorder caused by antibodies that over-stimulate the thyroid, causing excessive thyroid hormone production. The firm also develops therapeutics targeting erythroferrone for the treatment of iron deficiency and iron overload disorders. The company was founded by David Campbell on September 5, 2014 and is headquartered in San Diego, CA.

Enlibrium, Inc. provides medical services. It develops novel drugs based on the anti-cancer activity of metformin and designed to reduce cancer energy production to treat a range of cancer types. The company was founded by Michael Jung and Richard Pietras and is headquartered in La Jolla, CA.

Adrenergics, Inc. develops novel therapeutics to treat dilated cardiomyopathy. The company was founded by David Campbell and is headquartered in San Diego, CA.